FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124867980> ?p ?o ?g. }

• W3124867980 endingPage "75" @default.
• W3124867980 startingPage "65" @default.
• W3124867980 abstract "Early diagnosis and treatment of multiple sclerosis (MS) with disease-modifying therapy (DMT) can reduce relapse number and severity, which has cost implications. We describe treatment patterns, healthcare utilization, and cost among MS patients newly initiating DMTs (index).DMT-naïve adults with 12 months' continuous enrollment pre- and post-index and ≥2 MS claims (2009‒2018) were identified from the Optum Clinformatics Data Mart database. Treatment adherence and persistence were measured as time on index DMT. Relapses were identified using a validated claims-based algorithm. All-cause and MS-related healthcare expenditures and utilization were captured pre- and post-index. Outcomes were stratified by route of administration. Multivariate analyses assessed differences in outcomes and costs.The analysis included 5906 MS patients (mean age, 46.6 years). The majority initiated injectable (63.5%) followed by oral (28.8%) and infusion (7.7%) DMTs. Post-index, 45.3% of patients were nonadherent and 39.4% were nonpersistent. Relapse rates decreased from pre- to post-index (oral: 24.3%‒16.1%; injectable: 25.0%‒17.1%; infusion: 29.3%‒15.5%). Post-index mean (SD) all-cause total costs were lowest with oral ($70,970 [$36,681]) vs injectable ($82,521 [$58,569]) and infusion ($80,871 [$49,627]) DMTs. MS-related total costs were lowest with oral ($65,149 [$65,133]) vs injectable ($76,197 [$60,204]) and infusion ($72,703 [$47,287]) DMTs. Multivariate analysis showed no differences between oral and injectable DMTs in adherence, persistence, or relapse rate; however, oral DMTs had significantly lower all-cause and MS-related costs.With similar outcomes across DMT administration routes, initiating the least costly DMT may be warranted for many patients. In newly treated MS patients, the need exists to improve adherence and persistence." @default.
• W3124867980 created "2021-02-01" @default.
• W3124867980 creator A5000778444 @default.
• W3124867980 creator A5010761420 @default.
• W3124867980 creator A5060985600 @default.
• W3124867980 creator A5069726595 @default.
• W3124867980 date "2021-01-01" @default.
• W3124867980 modified "2023-10-16" @default.
• W3124867980 title "Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients" @default.
• W3124867980 cites W134576514 @default.
• W3124867980 cites W1971222758 @default.
• W3124867980 cites W1998024620 @default.
• W3124867980 cites W2014094373 @default.
• W3124867980 cites W2022502930 @default.
• W3124867980 cites W2029836048 @default.
• W3124867980 cites W2034896241 @default.
• W3124867980 cites W2049566645 @default.
• W3124867980 cites W2080458330 @default.
• W3124867980 cites W2132555717 @default.
• W3124867980 cites W2143953700 @default.
• W3124867980 cites W2181407021 @default.
• W3124867980 cites W2493463222 @default.
• W3124867980 cites W2502213024 @default.
• W3124867980 cites W2608396028 @default.
• W3124867980 cites W2739935697 @default.
• W3124867980 cites W2777074421 @default.
• W3124867980 cites W2799345901 @default.
• W3124867980 cites W2800924304 @default.
• W3124867980 cites W2911658427 @default.
• W3124867980 cites W4319308236 @default.
• W3124867980 cites W3021462274 @default.
• W3124867980 doi "https://doi.org/10.2147/ceor.s288296" @default.
• W3124867980 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7837567" @default.
• W3124867980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33519217" @default.
• W3124867980 hasPublicationYear "2021" @default.
• W3124867980 type Work @default.
• W3124867980 sameAs 3124867980 @default.
• W3124867980 citedByCount "8" @default.
• W3124867980 countsByYear W31248679802021 @default.
• W3124867980 countsByYear W31248679802022 @default.
• W3124867980 countsByYear W31248679802023 @default.
• W3124867980 crossrefType "journal-article" @default.
• W3124867980 hasAuthorship W3124867980A5000778444 @default.
• W3124867980 hasAuthorship W3124867980A5010761420 @default.
• W3124867980 hasAuthorship W3124867980A5060985600 @default.
• W3124867980 hasAuthorship W3124867980A5069726595 @default.
• W3124867980 hasBestOaLocation W31248679801 @default.
• W3124867980 hasConcept C126322002 @default.
• W3124867980 hasConcept C203014093 @default.
• W3124867980 hasConcept C2776036978 @default.
• W3124867980 hasConcept C2780640218 @default.
• W3124867980 hasConcept C71924100 @default.
• W3124867980 hasConceptScore W3124867980C126322002 @default.
• W3124867980 hasConceptScore W3124867980C203014093 @default.
• W3124867980 hasConceptScore W3124867980C2776036978 @default.
• W3124867980 hasConceptScore W3124867980C2780640218 @default.
• W3124867980 hasConceptScore W3124867980C71924100 @default.
• W3124867980 hasLocation W31248679801 @default.
• W3124867980 hasLocation W31248679802 @default.
• W3124867980 hasLocation W31248679803 @default.
• W3124867980 hasLocation W31248679804 @default.
• W3124867980 hasOpenAccess W3124867980 @default.
• W3124867980 hasPrimaryLocation W31248679801 @default.
• W3124867980 hasRelatedWork W2079246512 @default.
• W3124867980 hasRelatedWork W2103925177 @default.
• W3124867980 hasRelatedWork W2161929451 @default.
• W3124867980 hasRelatedWork W2281794554 @default.
• W3124867980 hasRelatedWork W2327660953 @default.
• W3124867980 hasRelatedWork W2391832248 @default.
• W3124867980 hasRelatedWork W2904853615 @default.
• W3124867980 hasRelatedWork W3025003623 @default.
• W3124867980 hasRelatedWork W3149632530 @default.
• W3124867980 hasRelatedWork W3158485242 @default.
• W3124867980 hasVolume "Volume 13" @default.
• W3124867980 isParatext "false" @default.
• W3124867980 isRetracted "false" @default.
• W3124867980 magId "3124867980" @default.
• W3124867980 workType "article" @default.